Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2024 Nov 1

PMID 39485057

Authors

Anne E Dodson

Sol Shenker

Pamela Sullivan

Sumeet U Nayak

Chris Middleton

Michael McGuire

Edmond Chipumuro

Yuji Mishina

Erica R Tobin

Louise Cadzow

Andrew A Wylie

Dipen Sangurdekar

Affiliations

Soon will be listed here.

Abstract

HRD is common in cancer and can be exploited therapeutically, as it sensitizes cells to DNA-damaging agents. Here, we scored more than 1,300 cancer cell lines for HRD using two different bioinformatic approaches, thereby enabling large-scale analyses that provide insights into the etiology and features of HRD.

Citing Articles

Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breast.

Sottnik J, Shackleford M, Nesiba C, Richer A, Swartz J, Rowland C bioRxiv. 2024; .

PMID: 39677775 PMC: 11642799. DOI: 10.1101/2023.10.29.564555.

References

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

Rempel E, Kluck K, Beck S, Ourailidis I, Kazdal D, Neumann O . Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD). NPJ Precis Oncol. 2022; 6(1):36. PMC: 9184602. DOI: 10.1038/s41698-022-00276-6. View

Wasylishen A, Lozano G . Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. Cold Spring Harb Perspect Med. 2016; 6(8). PMC: 4968169. DOI: 10.1101/cshperspect.a026211. View

Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. DOI: 10.1038/nature03445. View

Lakhani S, Reis-Filho J, Fulford L, Penault-Llorca F, van der Vijver M, Parry S . Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005; 11(14):5175-80. DOI: 10.1158/1078-0432.CCR-04-2424. View

Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M . BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol Oncol. 2013; 7(3):567-79. PMC: 4106023. DOI: 10.1016/j.molonc.2012.12.007. View

Adam S, Rossi S, Moatti N, De Marco Zompit M, Xue Y, Ng T . The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer. Nat Cancer. 2022; 2(12):1357-1371. DOI: 10.1038/s43018-021-00266-w. View

van der Wiel A, Schuitmaker L, Cong Y, Theys J, Van Hoeck A, Vens C . Homologous Recombination Deficiency Scar: Mutations and Beyond-Implications for Precision Oncology. Cancers (Basel). 2022; 14(17). PMC: 9454578. DOI: 10.3390/cancers14174157. View

Takamatsu S, Murakami K, Matsumura N . Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries. Sci Data. 2024; 11(1):171. PMC: 10847511. DOI: 10.1038/s41597-024-03018-4. View

10.

Wang B, Varela-Eirin M, Brandenburg S, Hernandez-Segura A, van Vliet T, Jongbloed E . Pharmacological CDK4/6 inhibition reveals a p53-dependent senescent state with restricted toxicity. EMBO J. 2022; 41(6):e108946. PMC: 8922251. DOI: 10.15252/embj.2021108946. View

11.

Esteller M, Silva J, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E . Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000; 92(7):564-9. DOI: 10.1093/jnci/92.7.564. View

12.

Leibowitz B, Dougherty B, Bell J, Kapilivsky J, Michuda J, Sedgewick A . Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort. BMC Cancer. 2022; 22(1):587. PMC: 9148513. DOI: 10.1186/s12885-022-09669-z. View

13.

Ghandi M, Huang F, Jane-Valbuena J, Kryukov G, Lo C, McDonald 3rd E . Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019; 569(7757):503-508. PMC: 6697103. DOI: 10.1038/s41586-019-1186-3. View

14.

Pacini C, Dempster J, Boyle I, Goncalves E, Najgebauer H, Karakoc E . Integrated cross-study datasets of genetic dependencies in cancer. Nat Commun. 2021; 12(1):1661. PMC: 7955067. DOI: 10.1038/s41467-021-21898-7. View

15.

Ryan C, Bajrami I, Lord C . Synthetic Lethality and Cancer - Penetrance as the Major Barrier. Trends Cancer. 2018; 4(10):671-683. DOI: 10.1016/j.trecan.2018.08.003. View

16.

Ladan M, van Gent D, Jager A . Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation. Cancers (Basel). 2021; 13(5). PMC: 7957671. DOI: 10.3390/cancers13051004. View

17.

Chiang Y, Lin P, Cheng W . Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction. Front Oncol. 2021; 11:675972. PMC: 8551835. DOI: 10.3389/fonc.2021.675972. View

18.

ONeil N, Bailey M, Hieter P . Synthetic lethality and cancer. Nat Rev Genet. 2017; 18(10):613-623. DOI: 10.1038/nrg.2017.47. View

19.

Marquard A, Eklund A, Joshi T, Krzystanek M, Favero F, Wang Z . Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res. 2015; 3:9. PMC: 4443545. DOI: 10.1186/s40364-015-0033-4. View

20.

Nguyen L, Martens J, Van Hoeck A, Cuppen E . Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020; 11(1):5584. PMC: 7643118. DOI: 10.1038/s41467-020-19406-4. View